In an effort to continue evaluating and improving our Long Term Care underwriting processes, the following changes have been made and will take effect July 15, 2015:
Partner Declination Process
In the event where one partner is declined, Underwriting will now communicate available options to the producer/designated contact to consider. These may include:
- Spouse Security Benefit
- Withdrawal vs. Issue
A request will be made to have a decision within 7 days.
Note: Upon issue, the applicant will now be sent a letter that the policy has been issued in order to assist in timely policy delivery.
Missing Information
- Applications will now be withdrawn after 90 days instead of 60 days (except in CA and MO).
- Applications will now be considered valid for 90 days instead of 120 days in order to coincide with the withdrawal cycle.
Note: Coverage Effective Date (CED) selection will now be strictly enforced.
Labs/Blood Work
Options to determine insurability may now include:
- A1C for applicant with diabetes at underwriter discretion and our expense
- PSA for applicant with prostate disorders at underwriter discretion and our expense
Authorization to Release Information:
Additional details will now be provided on declines directly to the producer or designated contact if the Authorization for Release of Information (M28704) has been submitted.
The following revisions will be made to the MutualCare® Solutions Product and Underwriting Guide (32050). You will be able to order your updated copy of the Product and Underwriting guide soon. You may view the guide on Sales Professional Access in the Forms and Materials section.
Product/Program Revisions
- Additional description has been added to the Compound Inflation with Buy-up Option
- Common Employer Program: Now clarified as a referral program. Requirements and included additional clarification that the policy is not ERISA compliant.
- Association/Sponsored Group: Clarification of guidelines and processes have been provided
- E- App Section: Included that the e-app is now supported and noted accordingly in the Steps to Completing the Application section
Underwriting Revisions
- Added the following uninsurable medications for drug abuse:
- Suboxone
- Naloxone
- Latuda
- Diabetic changes: Diabetes with Coronary Artery Disease or other heart disease or disorder with tobacco use in last 12 months is now a decline
- Elimination period reduced from 180 days to 90 days for the following conditions:
- Diabetes with retinal artery occlusion, single episode
- NASH with mild fibrosis
- Polycythermia Vera
- Added Retinal Artery Occlusion, single episode Class II, 2 years
- Clarification on Sleep Apnea: require a 3 month wait period
How to Order
The MutualCare® Solutions Product & Underwriting Guide can be viewed on Sales Professional Access in the Forms and Materials Section and ordered using your normal ordering channels.
If you have any questions please contact Sales Support at (800) 693-6083 or email sales.support@mutualofomaha.com